It will list 5 million shares at between $14 and $16 each to give an initial market capitalisation of about $215m, were it to price in the middle of its range.

Celgene owns 14.5% of Epizyme ahead of the initial public offering (IPO), after investing the portfolio company's series C round.

Walter Greenblatt & Associates (member FINRA, SIPC), a life-science focused investment bank, served as the financial adviser to Callidus Biopharma in both transactions.

Biogen Idec-backed Portola Pharmaceuticals set to raise around $103.2m on Nasdaq with $469m market cap

Massachusetts-backed Isis Pharmaceuticals receives $3.5m milestone payment from Biogen for battle against spinal muscular atrophy.